Compound class:
Synthetic organic
Comment: 852A is a soluble agonist of Toll-like receptor 7 (TLR7) [5]. It has been clinically investigated for potential anti-cancer activity [1-4,6].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖ |
|
No information available. |
Summary of Clinical Use |
852A has completed Phase 2 clinical trials in patients with metastatic melanoma (NCT00189332) and breast, ovarian, endometrial and cervical cancers (NCT00319748). An additional Phase 2 trial in hematologic malignancies (NCT00276159) was terminated [6]. Click here to link to ClinicalTrials.gov's full list of 852A trials. |
Clinical Trials | |||||
Clinical Trial ID | Title | Type | Source | Comment | References |
NCT00189332 | Use of 852A in Metastatic Cutaneous Melanoma. | Phase 2 Interventional | Pfizer | ||
NCT00276159 | Study of Immune Response Modifier in the Treatment of Hematologic Malignancies | Phase 2 Interventional | Masonic Cancer Center, University of Minnesota | ||
NCT00319748 | Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers | Phase 2 Interventional | Masonic Cancer Center, University of Minnesota |